Results 141 to 150 of about 40,867 (262)

Denosumab and the Rebound Effect: Current Aspects of Osteoporosis Therapy (Review)

Безопасность и риск фармакотерапии
INTRODUCTION. Osteoporosis is a leading cause of morbidity, disability, reduced quality of life, and premature mortality in the elderly population. Denosumab is a treatment for osteoporosis; however, denosumab discontinuation may cause a rebound effect ...
N. Yu. Velts, O. V. Velts, R. N. Alyautdin   +2 more
doaj   +1 more source

Oral Health Screening Prior to Oncological Treatment—The Helsinki Protocol

Oral Diseases, EarlyView.
ABSTRACT Objectives Oncological treatments can have adverse effects on oral health and cause long‐term complications such as osteonecrosis. This retrospective study investigated the oral health of head and neck cancer patients before radiotherapy and patients with multiple myeloma, breast, prostate, lung, and kidney cancers before antiresorptive ...
Jemina Järvinen, Johanna Uittamo, Hanna Välimaa, Tero Puolakkainen, Aleksi Haapanen   +4 more
wiley   +1 more source

Factors affecting the efficacy of nonsurgical therapy of peri‐implantitis

Periodontology 2000, EarlyView.
Abstract Objectives and Materials and Methods This article critically reviews the current knowledge on the factors influencing the efficacy of non‐surgical therapy (NST) of peri‐implantitis, taking also advantage of the know‐how from periodontitis management.
Elena Calciolari, Federico Rivara, Nikolaos Donos, Jérôme F. Lasserre, Selena Toma   +4 more
wiley   +1 more source

Measuring the Impact of the Substitution of Innovator Biologics With Biosimilars on Uptake and Costs Among Ontario Public Drug Benefit Recipients

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1476-1484, June 2026.
In Ontario, biologics have historically represented a small proportion of public drug claims but a large proportion of spending. Biosimilars, lower cost alternatives to biologics, offer a potential solution to the rising spending on biologics. From March 2023 to January 2024, the Ontario Ministry of Health required public drug program beneficiaries on ...
Anita Iacono, Martin K. H. Ho, Joanna Yang, Tonya Campbell, William Wynne, Dana Shearer, Lene Andersen, Eric Majer, Shaleesa Ledlie, Mina Tadrous, Tara Gomes   +10 more
wiley   +1 more source

Denosumab treatment in the management of patients with advanced prostate cancer: clinical evidence and experience

Therapeutic Advances in Urology, 2017
Osteoprotective therapies have become an essential component in the management of advanced prostate cancer (PC) patients as bone metastases (BMs) have a major impact on morbidity and mortality.
Miriam Hegemann, Jens Bedke, Arnulf Stenzl, Tilman Todenhöfer   +3 more
doaj   +1 more source

Romosozumab and Denosumab Combination Therapy After Denosumab in Postmenopausal Osteoporosis

Arthritis &Rheumatology, Volume 78, Issue 5, Page 1176-1183, May 2026.
Objective Transition from long‐term denosumab (Dmab) to parathyroid hormone‐analogs or romosozumab (Romo) might expose patients to the risk of the so‐called rebound phenomenon. Adding Romo to Dmab might represent an option in patients experiencing a fracture while on Dmab.
Giovanni Adami, Francesco Pollastri, Angelo Fassio, Filippo Montanari, Anna Piccinelli, Camilla Benini, Emma Pasetto, Carmen Dartizio, Davide Gatti, Maurizio Rossini, Ombretta Viapiana   +10 more
wiley   +1 more source

Bone scan index rise prior to osteonecrosis of the jaw with bone‐modifying agents in prostate cancer

BJUI Compass, Volume 7, Issue 5, May 2026.
Abstract Objective This study aimed to evaluate the maximum bone scan index in the jaw (BSIJmax) before the development of clinical medication‐related osteonecrosis of the jaw (MRONJ) in patients with prostate cancer. Methods We retrospectively analysed 135 patients with prostate cancer and bone metastases who received bone‐modifying agents (BMAs ...
Masaru Tani, Koji Hatano, Takashi Kamiya, Masatoshi Konishi, Atsuki Matsukawa, Hiromu Horitani, Syunsuke Inoguchi, Tomohiro Kanaki, Akihiro Yoshimura, Yuki Horibe, Yutong Liu, Nesrine Sassi, Toshiki Oka, Yohei Okuda, Gaku Yamamichi, Yu Ishizuya, Takuji Hayashi, Yoshiyuki Yamamoto, Taigo Kato, Tadashi Watabe, Atsunari Kawashima, Kayako Isohashi, Norio Nonomura   +22 more
wiley   +1 more source

Teriparatide in Two Patients With Mucopolysaccharidosis Type IVB

JIMD Reports, Volume 67, Issue 3, May 2026.
ABSTRACT Mucopolysaccharidosis Type IV is a multisystem lysosomal storage disease characterized by severe skeletal dysplasia resulting from impaired degradation of the glycosaminoglycans keratan sulfate and chondroitin‐6‐sulfate. The condition is classified into Types A and B based on the underlying enzyme deficiency.
Mark Wijnen, Evert F. S. van Velsen, J. Gert‐Jan Milhous, Esmee Oussoren, Bram C. J. van der Eerden, Margreet A. E. M. Wagenmakers   +5 more
wiley   +1 more source

The Osteoporosis Society of Hong Kong (OSHK): 2013 OSHK Guideline for Clinical Management of Postmenopausal Osteoporosis in Hong Kong [PDF]

, 2013
published_or_final_versio
Cheung, SKW, Cheung, TC, Choi, PTF, Chow, SLE, Ho, HYA, Ip, TP, Kan, SYA, Kung, WCA, Lee, KK, Leung, KLF, Leung, YYJ, Lo, STS, Sy, CT, Wong, YW   +13 more
core  

Pathophysiology and Molecular Signalling in Osteoporosis: Linking Risk Factors to Bone Loss

Journal of Cellular and Molecular Medicine, Volume 30, Issue 9, May 2026.
ABSTRACT Osteoporosis is a prevalent skeletal disorder characterised by progressive reduction in bone mass, microarchitectural deterioration, and increased fracture susceptibility. In India, approximately one‐third of the elderly population is affected by bone‐related disorders, and the global burden of osteoporosis continues to rise.
Pramoda G., Kamini Shivhare, Piyush Kumar Gupta, Amirhossein Sahebkar, Prashant Kesharwani, Rahul Shukla   +5 more
wiley   +1 more source